相关临床试验
61
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
9.8%
已完成
9
14.8%
尚未招募
12
19.7%
招募中
32
52.5%
终止
1
1.6%
撤回
1
1.6%
暂无批准数据
- Bascom Palmer Eye Institute ranked No. 1 in ophthalmology for the 25th consecutive year, one of the longest-running streaks in American medicine. - Sylvester Comprehensive Cancer Center climbed to No. 23 nationally and earned the No. 1 cancer program ranking in Florida, up from No. 45 last year. - Neurology & Neurosurgery entered the Top 15 for the first time at No. 14 nationally, while Cardiology, Heart & Vascular Surgery debuted in the Top 50. - Five additional specialties earned high-performing marks, placing them among the top 10% of hospitals nationwide.
- Researchers identified a panel of 19 blood proteins, including neurofilament light chain (NfL), that can estimate time to ALS symptom onset with an average error of approximately 18 months. - The study analyzed plasma samples from 137 participants in the NIH-funded Pre-symptomatic Familial ALS (Pre-fALS) study using high-throughput proteomic analysis, identifying 92 differentially expressed proteins. - Predictive models were validated across time horizons from six months to five years and produced similar results using UK Biobank data, suggesting broader population relevance. - The findings support the ATLAS clinical trial, which is evaluating tofersen as a preventative therapy in pre-symptomatic ALS carriers in partnership with Biogen.
- Johns Hopkins researchers achieved 100% long-term success in treating ventricular tachycardia using personalized digital heart twins, compared to traditional ablation's 60% success rate. - The FDA-approved TWIN-VT trial involved 10 patients who remained arrhythmia-free more than a year after treatment, with eight patients completely off anti-arrhythmia medications. - Digital twin technology creates precise virtual replicas of patients' hearts using MRI data, allowing doctors to test and optimize ablation procedures before treating the actual patient. - The approach targets only critical heart tissue areas, potentially making procedures shorter, safer, and more effective while reducing tissue damage and repeat procedures.
- 4DMedical's CT:VQ™ technology received CE Mark certification, enabling commercial launch across the European Union's 450 million population healthcare market. - The world's first non-contrast ventilation-perfusion imaging solution generates functional lung insights from routine CT scans without requiring radiotracers or specialized nuclear medicine infrastructure. - The company secured AU$83 million in private placement funding to support European expansion, building on successful deployment at six leading U.S. academic medical centers. - CT:VQ™ addresses the clinical gap between structural imaging and functional lung assessment, targeting approximately 400,000 annual nuclear VQ scans performed across the EU.
